The mutant IDH1 inhibitors ivosidenib [61, 62] and olutasidenib [63] and the mutant IDH2 inhibitor enasidenib [64, 65] relieve this differentiation block and are approved by the FDA as single agents for the treatment of IDH1mut and IDH2mut AML, respectively. This evidence concerns the gene IDH1 and acute myeloid leukemia.